CEL-SCI Corporation (CVM)

1,4200 -0,0900 (-5,96%) Börsenschluss: 04:00PM EDT

CEL-SCI Corporation

8229 Boone Boulevard
Suite 802
Vienna, VA 22182
United States
703 506 9460
https://cel-sci.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Geert R. Kersten Esq.	Chief Executive & Financial Officer, Treasurer and Director	702,79k	N/A	1959
Ms. Patricia B. Prichep	Senior VP of Operations & Corporate Secretary	295,18k	N/A	1951
Dr. Eyal Talor Ph.D.	Chief Scientific Officer	351,88k	N/A	1956
Dr. Daniel H. Zimmerman Ph.D.	Senior Vice President of Research & Cellular Immunology	46,08k	N/A	1941
Mr. John Cipriano	Senior Vice President of Regulatory Affairs	246,97k	N/A	1942

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Corporate Governance

CEL-SCI Corporations ISS Governance QualityScore, Stand 1. Mai 2024, lautet 10. Die grundlegenden Scores sind Audit: 10, Vorstand: 10, Shareholderrechte: 6, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.